

Johanna Svensson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4909620/publications.pdf>

Version: 2024-02-01

25
papers

747
citations

567281

15
h-index

580821

25
g-index

25
all docs

25
docs citations

25
times ranked

785
citing authors

#	ARTICLE	IF	CITATIONS
1	Individualised ¹⁷⁷ Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1480-1489.	6.4	144
2	Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷ Lu-DOTATATE treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 947-955.	6.4	79
3	[¹⁷⁷ Lu- ³ Tyr]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney. World Journal of Surgery, 2010, 34, 1368-1372.	1.6	62
4	The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer, 2022, 29, 1-14.	3.1	62
5	Feasibility of simplifying renal dosimetry in ¹⁷⁷ Lu peptide receptor radionuclide therapy. EJNMMI Physics, 2018, 5, 12.	2.7	60
6	Bone Marrow Absorbed Doses and Correlations with Hematologic Response During ¹⁷⁷ Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. Journal of Nuclear Medicine, 2019, 60, 1406-1413.	5.0	41
7	A novel planar image-based method for bone marrow dosimetry in ¹⁷⁷ Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Physics, 2016, 3, 21.	2.7	36
8	Comparison of methods for estimation of the intravoxel incoherent motion (IVIM) diffusion coefficient (D) and perfusion fraction (f). Magnetic Resonance Materials in Physics, Biology, and Medicine, 2018, 31, 715-723.	2.0	36
9	Nephrotoxicity profiles and threshold dose values for [¹⁷⁷ Lu]-DOTATATE in nude mice. Nuclear Medicine and Biology, 2012, 39, 756-762.	0.6	34
10	Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based ¹⁷⁷ Lu-DOTATATE treatment of NET patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3830-3840.	6.4	30
11	Radiation exposure of the spleen during ¹⁷⁷ Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume. EJNMMI Physics, 2016, 3, 15.	2.7	28
12	Deep-Learning Generation of Synthetic Intermediate Projections Improves ¹⁷⁷ Lu SPECT Images Reconstructed with Sparsely Acquired Projections. Journal of Nuclear Medicine, 2021, 62, 528-535.	5.0	25
13	Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial. World Journal of Surgery, 2018, 42, 506-513.	1.6	23
14	Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Physics, 2015, 2, 10.	2.7	20
15	Dosimetric Analysis of the Short-Ranged Particle Emitter ¹⁶¹ Tb for Radionuclide Therapy of Metastatic Prostate Cancer. Cancers, 2021, 13, 2011.	3.7	19
16	Pituitary Function after High-Dose ¹⁷⁷ Lu-DOTATATE Therapy and Long-Term Follow-Up. Neuroendocrinology, 2021, 111, 344-353.	2.5	12
17	Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. Cancers, 2021, 13, 2035.	3.7	7
18	Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in ¹⁷⁷ Lu-DOTATATE Treatments. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 335-343.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Simulation Model of Microsphere Distribution for Selective Internal Radiation Therapy Agrees With Observations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 414-421.	0.8	5
20	Optimizing the Schedule of PARP Inhibitors in Combination with ¹⁷⁷ Lu-DOTATATE: A Dosimetry Rationale. <i>Biomedicines</i> , 2021, 9, 1570.	3.2	4
21	Autoradiography and biopsy measurements of a resected hepatocellular carcinoma treated with ⁹⁰ yttrium radioembolization demonstrate large absorbed dose heterogeneities. <i>Advances in Radiation Oncology</i> , 2018, 3, 439-446.	1.2	3
22	Evaluation of the Spatial Resolution In monte Carlo-Based Spect/Ct Reconstruction Of ¹¹¹ In-Octreotide Images. <i>Radiation Protection Dosimetry</i> , 2021, 195, 319-326.	0.8	3
23	Activity Concentration Estimation in Automated Kidney Segmentation Based on Convolution Neural Network Method for ¹⁷⁷ Lu-SPECT/CT Kidney Dosimetry. <i>Radiation Protection Dosimetry</i> , 2021, 195, 164-171.	0.8	3
24	Clinical outcomes in cancer patients with COVID-19 in Sweden. <i>Acta Oncologica</i> , 2021, 60, 1572-1579.	1.8	3
25	IMPROVED PLANAR KIDNEY ACTIVITY CONCENTRATION ESTIMATE BY THE POSTERIOR VIEW METHOD IN ¹⁷⁷ Lu-DOTATATE TREATMENTS. <i>Radiation Protection Dosimetry</i> , 2016, 169, 259-266.	0.8	2